CYP2B6 non-coding variation associated with smoking cessation is also associated with differences in allelic expression, splicing, and nicotine metabolism independent of common amino-acid changes.
The Cytochrome P450 2B6 (CYP2B6) enzyme makes a small contribution to hepatic nicotine metabolism relative to CYP2A6, but CYP2B6 is the primary enzyme responsible for metabolism of the smoking cessation drug bupropion. Using CYP2A6 genotype as a covariate, we find that a non-coding polymorphism in C...
Main Authors: | A Joseph Bloom, Maribel Martinez, Li-Shiun Chen, Laura J Bierut, Sharon E Murphy, Alison Goate |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3829832?pdf=render |
Similar Items
-
The Impact of CYP2A6 Genotype on Smoking Cessation in an Extended Nicotine Patch Therapy Clinical Trial
by: Mroziewicz, Margaret
Published: (2009) -
The Impact of CYP2A6 Genotype on Smoking Cessation in an Extended Nicotine Patch Therapy Clinical Trial
by: Mroziewicz, Margaret
Published: (2009) -
Nicotine addiction and smoking cessation strategies
by: Michael Kourakos, et al.
Published: (2016-03-01) -
Association of tobacco industry denormalisation beliefs with smoking cessation and nicotine addiction in adolescent smokers
by: Jianjiu Chen, et al.
Published: (2018-10-01) -
Nicotine preloading for smoking cessation: the Preloading RCT
by: Paul Aveyard, et al.
Published: (2018-08-01)